CL2020001638A1 - Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945) - Google Patents
Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945)Info
- Publication number
- CL2020001638A1 CL2020001638A1 CL2020001638A CL2020001638A CL2020001638A1 CL 2020001638 A1 CL2020001638 A1 CL 2020001638A1 CL 2020001638 A CL2020001638 A CL 2020001638A CL 2020001638 A CL2020001638 A CL 2020001638A CL 2020001638 A1 CL2020001638 A1 CL 2020001638A1
- Authority
- CL
- Chile
- Prior art keywords
- papd5
- nucleic acid
- treatment
- acid molecule
- infection
- Prior art date
Links
Abstract
La presente invención se refiere a moléculas de ácidos nucleicos que son complementarias a tanto la proteína 5 que contiene el dominio asociado a PAP (PAPD5) como la proteína 7 que contiene el dominio asociado a PAP (PAPD7), que conducen a la inhibición de la expresión de tanto PAPD5 como PAPD7 al utilizar una única molécula de ácidos nucleicos. La invención proporciona además moléculas de ácidos nucleicos específicas de PAPD5 y PAPD7 para la utilización en el tratamiento y/o prevención de una infección por el VHB, en particular una infección crónica por el VHB. Se encuentra comprendida además en la presente invención una composición farmacéutica para la utilización en el tratamiento y/o prevención de una infección por el VHB.The present invention relates to nucleic acid molecules that are complementary to both protein 5 containing the PAP-associated domain (PAPD5) and protein 7 containing the PAP-associated domain (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 using a single nucleic acid molecule. The invention further provides PAPD5 and PAPD7 specific nucleic acid molecules for use in the treatment and / or prevention of an HBV infection, in particular a chronic HBV infection. A pharmaceutical composition for use in the treatment and / or prevention of HBV infection is further encompassed by the present invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17196554 | 2017-10-16 | ||
EP17208056 | 2017-12-18 | ||
CL2020000945A CL2020000945A1 (en) | 2017-10-16 | 2020-04-08 | Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020001638A1 true CL2020001638A1 (en) | 2020-10-16 |
Family
ID=73045719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020001638A CL2020001638A1 (en) | 2017-10-16 | 2020-06-17 | Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945) |
Country Status (1)
Country | Link |
---|---|
CL (1) | CL2020001638A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11191775B2 (en) | 2016-06-17 | 2021-12-07 | Hoffmann-La Roche Inc. | PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection |
US11484546B2 (en) | 2017-10-16 | 2022-11-01 | Hoffman-La Roche Inc. | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection |
-
2020
- 2020-06-17 CL CL2020001638A patent/CL2020001638A1/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11191775B2 (en) | 2016-06-17 | 2021-12-07 | Hoffmann-La Roche Inc. | PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection |
US11534452B2 (en) | 2016-06-17 | 2022-12-27 | Hoffmann-La Roche Inc. | Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection |
US11484546B2 (en) | 2017-10-16 | 2022-11-01 | Hoffman-La Roche Inc. | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003464A (en) | NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION. | |
PE20190443A1 (en) | NUCLEIC ACID MOLECULES FOR THE REDUCTION OF PAPD5 OR PAPD7 mRNA TO TREAT HEPATITIS B INFECTION | |
CL2017002230A1 (en) | Combined treatment with a tlr7 agonist and inhibitor of vhb capsid assembly. | |
AR112271A1 (en) | COMPOSITIONS INCLUDING AN INHIBITOR OF RNA POLYMERASE AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS | |
BR112018009009A2 (en) | combined therapy of an hbv capsid formation inhibitor and an interferon | |
BR112015028879A8 (en) | heterocyclic derivative compounds, pharmaceutical composition comprising said compounds and uses thereof | |
BR112019004560A2 (en) | combination treatment with tlr7 agonist and a hbv capsid formation inhibitor | |
UY37581A (en) | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | |
BR112016020199A8 (en) | human plasma kallikrein inhibitor compound, pharmaceutical composition comprising said compound, kit and its use | |
CL2020001146A1 (en) | New indole-2-carboxamides substituted with pyrazolopiperidine, of high activity, active against the hepatitis b virus (HBV). | |
BR112015009624A2 (en) | bruton tyrosine kinase inhibitors | |
BR112012024661A2 (en) | compound, pharmaceutical composition and method of treating a host infected with hepatitis c virus | |
BR112020020220A8 (en) | use of fubp1 inhibitors to treat hepatitis b virus infection | |
ECSP088208A (en) | NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | |
BR112013020042A2 (en) | hepatitis c virus inhibitors | |
CL2020001638A1 (en) | Nucleic acid molecule for the reduction of papd5 and papd7 mRNA in the treatment of hepatitis b infection. (divisional request 202000945) | |
AR114551A1 (en) | COMPOSITIONS OF hdRNA AGENTS AGAINST HEPATITIS B VIRUS (HBV) AND METHODS FOR THEIR USE | |
BR112019024549A2 (en) | glycopeptide-derived compounds and uses thereof | |
WO2009138146A3 (en) | Novel therapeutic agents against hepatitis | |
MX2020003473A (en) | Novel mek-inhibitor for the treatment of viral and bacterial infections. | |
CL2021000018A1 (en) | Oligonucleotides to modulate the expression of rtel1 | |
BR112022000971A2 (en) | Dihydropyrimidine derivatives and their use in the treatment of hbv infection or hbv-induced diseases | |
BR112015022134A2 (en) | compound, pharmaceutical composition, patch, stick, spray dispenser, tube or pen, and method of treating an infection | |
AR113771A1 (en) | NUCLEIC ACID MOLECULE FOR THE REDUCTION OF PAPD5 AND PAPD7 mRNA IN THE TREATMENT OF HEPATITIS B INFECTION | |
CO2023000116A2 (en) | Improved oligonucleotides to modulate fubp1 expression |